Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Neuro-Oncology Practice
|
February 7, 2025
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Vincent Fougner, Thomas Urup, Hans Skovgaard Poulsen, et al.
Frontiers in Bioengineering and Biotechnology
|
April 20, 2026
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids
Joana Leitão-Castro, Alexia Melanie Lopresti, Kamilla Westarp Zornhagen, et al.
Cells
|
February 12, 2026
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform
Silje Kjølle, Mario Presti, Jéssica de Pina Roque, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
BMC Cancer
|
February 23, 2023
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, et al.
Advanced Healthcare Materials
|
November 4, 2021
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor
Maria Rafaeva, Edward R Horton, Adina R D Jensen, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Neuro-Oncology
|
December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
François Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Neuro-Oncology Practice
|
February 7, 2025
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023
Vincent Fougner, Thomas Urup, Hans Skovgaard Poulsen, et al.
Frontiers in Bioengineering and Biotechnology
|
April 20, 2026
Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids
Joana Leitão-Castro, Alexia Melanie Lopresti, Kamilla Westarp Zornhagen, et al.
Cells
|
February 12, 2026
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform
Silje Kjølle, Mario Presti, Jéssica de Pina Roque, et al.
Journal of the National Cancer Institute
|
May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)
Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
BMC Cancer
|
February 23, 2023
ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial
Tina Kringelbach, Martin Højgaard, Kristoffer Rohrberg, et al.
Advanced Healthcare Materials
|
November 4, 2021
Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor
Maria Rafaeva, Edward R Horton, Adina R D Jensen, et al.
Nature Medicine
|
June 5, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results
Ezra Y Rosen, Timothy A Yap, Elisa Fontana, et al.
Neuro-Oncology
|
December 1, 2021
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
François Doz, Cornelis M van Tilburg, Birgit Geoerger, et al.
Page
of 2